Redx Pharma plc Result of AGM and Directorate change (8923Q)
02 March 2021 - 11:38PM
UK Regulatory
TIDMREDX
RNS Number : 8923Q
Redx Pharma plc
02 March 2021
REDX PHARMA PLC
("Redx" or "the Company")
Result of Annual General Meeting and Directorate change
Alderley Park, 2 March 2021 Redx Pharma (AIM:REDX), the drug
discovery and development Company focused on oncology and fibrosis,
today announces that its Annual General Meeting was held at 11.00
am on 2 March 2021, with all resolutions passed by substantial
majorities.
The table below sets out the details of the votes put to
shareholders
Resolution Resolution Number % of votes Number % of % of Total
numbe name of votes for & of votes votes votes votes
for & discretionary against against witheld cast
discretionary (including
withheld)
Receive the
Company's
annual
1 accounts 247,031,884 94.79% 13,571,429 5.21% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Re-appoint
RSM as
2 auditors 260,597,840 100% 200 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Elect Sarah
Gordon Wild
3 as a director 260,597,840 100% 200 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Elect Dr
Thomas Burt
4 as a director 260,597,840 100% 200 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Re-elect
Lisa Anson
5 as a director 260,603,513 100% 0 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Re-elect
Dr Bernd
Kirschbaum
6 as a director 260,598,040 100% 0 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Re-elect
Peter
Presland
7 as a director 260,603,513 100% 0 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Authorise
the directors
to allot
8 shares 260,594,551 100% 1,686 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
Disapply
pre-emption
9 rights 260,594,551 100% 2,389 0.00% 0.00% 260,604,013
--------------- --------------- --------------- ------------ ---------- ---------- ---------------
The Chairman, Iain Ross provided the following update:
"As the Company continues to progress its pipeline and expand
its operations, the Board has reviewed its composition and that of
the executive leadership team. As a result, a search for a US based
Chief Financial Officer has been initiated. James Mead will
continue in his role as Chief Financial Officer until a new
appointment has been made at which point Dr Mead will assume the
role of Chief Operating Officer. In conjunction with these changes,
Dr Mead will step down from the Board with immediate effect and
will cease to be a Director of the Company. Going forward, the
Board will therefore consist of five non-executive directors and
one executive director, the CEO. Finally on a personal basis I
would like to thank James for his contribution to the Board over
the last two years, and his ongoing commitment as a member of the
executive management team going forward."
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Broker) T: +44 20 3705
9330
Claes Spång/Chris Lee/David Wilson
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical proof of
concept. Redx's lead oncology asset, RXC004, is currently in a
phase 1 study in patients with advanced malignancies with top line
data expected in H1 2021 and the Company's selective ROCK2
inhibitor, RXC007, is expected to enter a phase 1 clinical study in
H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognized by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUUOURANUORAR
(END) Dow Jones Newswires
March 02, 2021 07:38 ET (12:38 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024